27,780 Alzheimer's and dementia studies in plain English, each scored out of 100.
Plasma lipocalin-2 levels were higher in preclinical AD compared with control subjects and associated with cerebrospinal fluid amyloid-beta42 levels but not cerebrospinal fluid tau or phosphorylated-tau181 levels. 3 key findings →
Design: cross-sectional Participants: 156 Evidence: low
Full summary, score breakdown and related studies → Original source
Six miRNAs (hsa-miR-128-3p, hsa-miR-144-5p, hsa-miR-146a-5p, hsa-miR-26a-5p, hsa-miR-29c-3p and hsa-miR-363-3p) were downregulated in the blood of individuals with low cognitive performance on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). 4 key findings →
Design: cross-sectional Participants: 830 Evidence: low
Full summary, score breakdown and related studies → Original source
Both total CogEvo and MMSE scores significantly decreased with age. 5 key findings →
Design: cross-sectional Participants: 209 Evidence: low
Full summary, score breakdown and related studies → Original source
The study included 1 789 participants (1 206 with AD, 111 with DLB, 49 with VaD, and 423 with NC). 5 key findings →
Design: cross-sectional Participants: 789 Evidence: low
Full summary, score breakdown and related studies → Original source
There were 719 respondents (276 people with dementia, 443 carers). 5 key findings →
Design: cross-sectional Participants: 276 Evidence: low
Full summary, score breakdown and related studies → Original source
Positron emission tomography (PET)-based staging of regional amyloid deposition has recently emerged as a promising tool for sensitive detection and stratification of pathology progression in Alzheimer's Disease (AD). 2 key findings →
Design: cross-sectional Participants: 403 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Widespread DMN FC changes were shown in frontal and posterior areas, as well as in the right hippocampus. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 124 eyes of 69 participants with PD (39 men [56.5%]; mean [SD] age, 71.7 [7.0] years) and 248 eyes of 137 control participants (77 men [56.2%]; mean [SD] age, 70.9 [6.7] years) were analyzed. 5 key findings →
Design: cross-sectional Participants: 69 Evidence: low
Full summary, score breakdown and related studies → Original source
ChT was increased in people with DS (pwDS) compared to Ctrl. 5 key findings →
Design: cross-sectional Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source
Regular musical activity as a complex multimodal lifestyle activity is proposed to be protective against age-related cognitive decline and Alzheimer's disease. 2 key findings →
Design: cross-sectional Participants: 70 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Overall, 5,146 participants were included. 5 key findings →
Design: cross-sectional Participants: 5,146 Evidence: low
Full summary, score breakdown and related studies → Original source
Metabolically healthy obese (MHO) individual is known to be defended from the metabolic complications of obesity. 2 key findings →
Design: cross-sectional Participants: 171 Evidence: low
Full summary, score breakdown and related studies → Original source
Blood-brain-barrier (BBB) dysfunction is a hallmark of aging and aging-related disorders, including cerebral small vessel disease and Alzheimer's disease. 4 key findings →
Design: cross-sectional Participants: 30 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 395 persons with dementia were included. 5 key findings →
Design: cross-sectional Participants: 395 Evidence: low
Full summary, score breakdown and related studies → Original source
Family caregivers of people with dementia (PWD) have a heavy care burden. 4 key findings →
Design: cross-sectional Participants: 270 Evidence: low
Full summary, score breakdown and related studies → Original source
The mean score for affiliate stigma of dementia family caregivers was 48.09 ± 16.38 (range: 22-86). 4 key findings →
Design: cross-sectional Participants: 727 Evidence: low
Full summary, score breakdown and related studies → Original source
Blacks and Hispanics were more prone to falsely positive perceptions of their cognitive function in the presence of cognitive impairment than non-Hispanic Whites. 3 key findings →
Design: cross-sectional Participants: 3,096 Evidence: low
Full summary, score breakdown and related studies → Original source
Positive associations between self-efficacy and language did not significantly differ across race/ethnicity, although the bivariate association between self-efficacy and language was not significant among Hispanics. 5 key findings →
Design: cross-sectional Participants: 548 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Multiple MTHFR coding variants were identified in this small Indonesian VaD cohort. 2 key findings →
Design: cross-sectional Participants: 17 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This study provides the first molecular characterization of MAPT gene variants in Indonesian patients with vascular dementia. 2 key findings →
Design: cross-sectional Participants: 17 Evidence: low
Full summary, score breakdown and related studies → Original source
Early identification of cognitive impairment in Parkinson’s disease (PD) has important clinical and research implications. 3 key findings →
Design: cross-sectional Participants: 136 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Brain degeneration in patients with Alzheimer's disease (AD) results from the accumulation of pathological amyloid- (Aβ) plaques and tau protein tangles, leading to altered plasma levels of biomarkers. 5 key findings →
Design: cross-sectional Participants: 40 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma proteins improved classification accuracy of AD pathology in cognitively-impaired older adults and appeared representative of amyloid pathology. 1 key finding →
Design: cross-sectional Participants: 72 Evidence: moderate
Full summary, score breakdown and related studies → Original source
CSF biomarkers of angiogenesis are increased in PD, and they are associated with gait difficulties, BBB dysfunction, WMLs, and CMB. 5 key findings →
Design: cross-sectional Participants: 100 Evidence: low
Full summary, score breakdown and related studies → Original source
Using blood samples from the publicly available ADNI research cohort (191 people with mild cognitive impairment or dementia), this study found the PrecivityAD2 blood test agreed with amyloid PET scans about 91% of the time. 3 key findings →
Design: cross-sectional Participants: 191 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,780 records, built mostly from automated pulls of Europe PMC (61.1% of the library) and OpenAlex (18.3%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →